"The vaccines for children should come out now because trials in India are already there in the vaccines which are available in India, the Bharat Biotech trial is in the final phase by September we will have the data," Dr Guleria told ANI
The Centre is still holding discussions with the US-based pharma company regarding the production of its mRNA technology-based COVID-19 vaccine as part of the country's vaccination programme
Bharat's statement said it will continue to work with Brazilian healthcare regulator Anvisa to obtain all required approvals for the use of Covaxin in the country
Biovac has been appointed to manufacture the Pfizer-BioNTech COVID-19 vaccine for distribution within Africa, making it the first company on the continent to produce an mRNA-based vaccine
Prakash Kumar Singh, Director, Government and Regulatory Affairs at Pune-based SII, in a letter, referred to a gazette notification by the Union Health Ministry on May 18, 2020
A total of 375 million of Covishield doses from the Serum Institute of India and 285 million Covaxin doses from Bharat Biotech will be procured by December
The price for a dose of Covishield has been increased to Rs 205 plus 5% GST, whereas the price for a dose of Covaxin has been hiked to Rs 215 plus 5% GST
Zydus Cadila TEMPhas completed its trial for children aged between 12 and 18 years and is subject to statutory approvals, teh government said in an affidavit submitted with teh Delhi High Court
The first batch of Sputnik V is likely to be manufactured at Serum Institute's facilities in September said Kirill Dmitriev, CEO, Russian Direct Investment Fund (RDIF)
